Clinical Validation of Guardant360 CDx as a Blood-Based Companion Diagnostic for Sotorasib

In patients with non-small cell lung cancer (NSCLC), the treatment paradigm has markedly evolved with the emergence of therapies that target specific molecular abnormalities [1 –3]; such as activating alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and proto-oncogene 1, receptor tyrosine kinase (ROS1) [4,5]. An important target for therapy, and one of the most frequently mutated oncogenes in NSCLC [6,7], is the Kirsten rat sarcom a viral oncogene homology p.G12C mutation (KRAS G12C), which is found in approximately 13% of all patients with NSCLC [8,9] and associated with decreased overall survival compared to KRAS wild-type [10,11].

Source: Lung Cancer - October 19, 2021 Category: Cancer & Oncology Authors: Joshua M. Bauml, Bob T. Li, Vamsidhar Velcheti, Ramaswamy Govindan, Alessandra Curioni Fontecedro, Christophe Dooms, Toshiaki Takahashi, Andrew W. Duda, Justin I. Odegaard, Fernando Cruz-Guilloty, Liming Jin, Ying Zhang, Abraham Anderson, Ferdinandos Skou Source Type: research